AstraZeneca

News

Roche's crovalimab matches Soliris in PNH, with fewer doses

Roche is preparing regulatory filings for its crovalimab antibody for rare disease paroxysmal nocturnal haemoglobinuria (PNH), after a phase 3 trial showed the drug was as

News

AstraZeneca partners Capitainer on biomarker project

Swedish medtech start-up Capitainer has started working with AstraZeneca on a project to use a device for sampling cell-free blood in clinical trial programmes.

News

Advantage pharma in 340B drug discounting dispute with HHS

A federal appeals court in the US has ruled in favour of three pharma companies in a dispute over the supply of discounted medicines to contract pharmacies with the Health

News

FDA pulls AZ's Evusheld for COVID, citing lack of efficacy

AstraZeneca's revenue boost from COVID-19 therapy Evusheld looks set to be curbed early, as the FDA withdraws authorisation for the antibody on the grounds that it is ineffective against mo

News

EU clears Enhertu for HER2-low breast cancer

The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be

News

Merck's Keytruda flunks another prostate cancer test

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial.

Roche's crovalimab matches Soliris in PNH, with fewer doses

AstraZeneca partners Capitainer on biomarker project

Advantage pharma in 340B drug discounting dispute with HHS

FDA pulls AZ's Evusheld for COVID, citing lack of efficacy

EU clears Enhertu for HER2-low breast cancer

Merck's Keytruda flunks another prostate cancer test

CHMP decision levels the playing field for GSK's RSV jab

How to meet your physicians where they are online

AstraZeneca

Editor's Picks